免疫联合治疗对髓源性抑制细胞作用的研究进展  

Research progress in the effect of combination immunotherapy on myeloid-derived suppressor cells

作　　者：雷凡 崔昭 秦雅含 张珂 彭美玉 Lei Fan;Cui Zhao;Qin Yahan;Zhang Ke;Peng Meiyu(Laboratory of Immune Microenvironment and Inflammatory Diseases Research Characteristics,Shandong Second Medical University,Weifang 261053,China)

机构地区：[1]山东第二医科大学免疫微环境与炎症性疾病研究特色实验室,潍坊261053

出　　处：《中华微生物学和免疫学杂志》2024年第11期992-998,共7页Chinese Journal of Microbiology and Immunology

基　　金：国家自然科学基金(81972695);山东省高等学校青创人才引育计划。

摘　　要：髓源性抑制细胞(myeloid-derived suppressor cells,MDSCs)是髓系来源的具有免疫抑制功能的异质性细胞群体。MDSCs通过抑制T细胞、NK细胞、巨噬细胞和B细胞的活性,并促进Treg的增殖等机制来使宿主对肿瘤的正常免疫应答受到抑制。因此,MDSCs是肿瘤免疫疗法的潜在靶点。然而,不论免疫治疗还是其他治疗,单药治疗的效果均有限,故免疫治疗联合其他治疗是一个突破性的结合。近年来,免疫治疗联合其他治疗已初见成效,效果优于单药治疗,已成为肿瘤治疗的研究热点,也是将来新的治疗方式。本文将免疫治疗联合化疗、放疗、中草药提取物及免疫治疗联合组合对MDSCs的作用的相关研究进展进行了总结,以期为临床应用免疫治疗为基础的联合肿瘤治疗措施提供理论支持。Myeloid-derived suppressor cells(MDSCs)are a heterogeneous cell population of myeloid origin with immunosuppressive function.MDSCs can inhibit the normal immune response of the host to tumor by inhibiting the activity of T cells,natural killer cells,macrophage,B cells,and promoting the proliferation of Treg and other mechanisms.Therefore,MDSCs are potential targets for tumor immunotherapy.However,whether immunotherapy or other treatments,the effectiveness of monotherapy is limited,so immunotherapy combined with other treatments is a breakthrough combination.In recent years,immunotherapy combined with other treatments has shown initial results,with better results than monotherapy.It has become a research hotspot in tumor treatment and a new treatment method in the future.This article summarized the research progress on the effects of immunotherapy combined with chemotherapy,radiotherapy,Chinese herbal extract and Immunotherapy combination on MDSCs,in order to provide theoretical support for the clinical application of immunotherapy based combined tumor treatment measures.

关 键 词：肿瘤 免疫联合治疗 髓源性抑制细胞 

分 类 号：R730.51[医药卫生—肿瘤]